Study explores patient-reported outcomes for UGN-102 in NMIBC - Urology Times

“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.

In this video, Angela M. Stover, PhD, discusses the rationale and notable findings from the Journal of Urology study, Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as F… [+222 chars]

full article...